➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Colorcon
Mallinckrodt
Johnson and Johnson
Harvard Business School

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Patent: 10,231,981

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,231,981
Title:Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
Inventor(s): Zhang; Xiaoping (Wayne, NJ), Terao; Kimio (Funabashi, JP), Harari; Olivier Alfred (London, GB)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) Hoffmann-La Roche Inc. (Little Falls, NJ)
Application Number:15/668,445
Patent Claims:see list of patent claims

Details for Patent 10,231,981

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 001 2010-01-08   Start Trial Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) Hoffmann-La Roche Inc. (Little Falls, NJ) 2030-11-08 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 002 2010-01-08   Start Trial Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) Hoffmann-La Roche Inc. (Little Falls, NJ) 2030-11-08 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 003 2010-01-08   Start Trial Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) Hoffmann-La Roche Inc. (Little Falls, NJ) 2030-11-08 RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) Hoffmann-La Roche Inc. (Little Falls, NJ) 2030-11-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Baxter
Colorcon
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.